Correlation of Hormone Receptor and HER-2/neu Expression with Clinicopathologic Parameters in Primary Breast Tumors

  • Published : 2016.07.01


Background: Breast cancer (BC) is a major health issue worldwide as well as in Pakistan. All women belonging to any race, ethnicity or lineage are in danger of developing breast cancer. Significant factors influencing the development of breast malignancies are the genetic background, environmental conditions, reproductive parameters, the consequences of female hormones both intrinsic and extrinsic, alteration of immune status, and biologic determinants. Materials and Methods: Overall 150 biopsy proven patients were included in the study. Samples were submitted for histopathology and determination of estrogen and progesterone receptor expression and HER-2/neu status. Associations with other characteristics like age, tumor stage, node involvement, histological grade were also studied. Results: Mean age at presentation was 46.7 years. The majority had invasive ductal carcinoma, 100 (84.7%), and were in stage pT3, 54 (45.7%). Important relationships (P<0.05) were found among ER, PR positivity, and Her 2 neu overexpression. However, no noteworthy link was identified amongst ER, PR, Her 2 neu and tumor grade, stage, age, lymph node involvement except for the menopausal status. Conclusions: In summary, breast cancer patients featured an advanced stage of disease, more lymph node involvement, and moderately high grade tumors and with more estrogen, progesterone receptor and HER-2 positive tumors.


  1. Ahmad A, Bano U, Gondal M, Khan A (2009). Her-2/neu Gene Overexpression in Breast Carcinoma and its Association with Clinicopathological Characteristics of the Disease. J Coll Phys Surg Pakistan, 19, 297-9.
  2. Alexander L, Malik IA, Aziz Z, et al (2002).Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet, 71, 595-606.
  3. Anders CK, Hsu DS, Broadwater G, et al (2008). Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol, 26, 3324-30.
  4. Azam M, Qureshi A, Mansoor S (2009). Comparison of estrogen receptors, progesterone receptors and HER-2/neu expression between primary and metastatic breast carcinoma. JPMA, 59, 736
  5. Badar F, Mahmood S, Faraz R, et al (2015). Epidemiology of breast cancer at the shaukat khanum memorial cancer hospital and research center. J College Physicians Surgeons Pakistan, 25, 738-742.
  6. Bardou VJ, Arpino G, Elledge RM, et al (2003). Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol, 21, 1973-9.
  7. Bauer K, Brown M, Cress R, et al (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer, 109, 1721-8.
  8. Benz CC, Scott GK, Sarup JC, et al (1993). Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7cells transfected with HER2/neu. Breast Cancer Res Treat, 24, 85-95.
  9. Davis SL, Eckhardt SG, Tentle JJr (2014). Diamond JR. Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Ther Adv Med Oncol, 6, 88-100.
  10. Dent R, Trudeau M, Pritchard KI, et al (2007). Triple negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13, 4429-34.
  11. Faheem M , Mahmood H, Khurram M, et al (2012). Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan. Ecancer, 6, 283.
  12. Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. Lyon, france: international agency for research on cancer; [Internet] [cited 2014 Jan 15].
  13. Fuqua SA, Cui Y, Lee AV, et al (2005). Insights into the role of progesterone receptors in breast cancer. J Clin Oncol, 23, 4 931-2.
  14. Gilani SI, Khurram M, Mazhar T, et al (2010). Knowledge, attitude and practice of a Pakistani female cohort towards breast cancer. J Pak Med Assoc, 60, 205-8.
  15. Gupta D, Gupta V, Marwah N, et al (2015). Correlation of hormone receptor expression with histologic parameters in benign and malignant breast tumors. Iranian J Pathol, 10, 23 - 34.
  16. Hammond ME, Hayes DF, Dowsett M, et al (2010). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol, 28, 2784-95.
  17. Kakarala M, Rozek L, Cote M, et al (2010). Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. - a SEER analysis. BMC Cancer, 10, 19.
  18. Khokher S, Qureshi MU, Riaz M, et al (2012). Clinicopathologic profile of breast cancer patients in Pakistan: ten years data of a local cancer hospital. Asian Pac J Cancer Prev, 13, 693-8.
  19. Konecny G, Pauletti G, Pegram M, et al (2003). Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast. J Natl Cancer Inst, 95, 142-53.
  20. Mahmood S, Rana TF, Ahmad M (2006). Common determinants of Ca Breast: a case control study in Lahore. Ann King Edward Med Coll, 12, 227-8.
  21. Mohammed H, Russell IA, Stark R, et al (2015). Progesterone receptor modulates $ER{\alpha}$ action in breast cancer. Nature, 523, 313-31.
  22. Moran MS, Gonsalves L, Goss DM, et al (2011).U.S. residing Indian-Pakistani versus non-hispanic white women: comparative analysis of clinical-pathologic features, treatment, and survival. Breast Cancer Res Treat, 128, 543-51.
  23. Oakman C, Viale G, Di Leo A (2010). Management of triple negative breast cancer. Breast, 19, 312-32.
  24. Peppercorn J, Perou C, Carey L (2008). Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest, 26, 1-10.
  25. Pietras RJ, Arboleda J, Reese DM, et al (1995). HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene, 10, 2435-46.
  26. Pimhanam C, Sangrajrang S, Ekpanyaskul C (2014). Tobacco Smoke Exposure and Breast Cancer Risk in Thai Urban Females. Asian Pac J Cancer Prev, 15, 7407-7411.
  27. Rakha E, El-Sayed M, Green A, et al (2007). Prognostic markers in triple-negative breast cancer. Cancer, 109, 25-32.
  28. Silberman A (2014). ER-positive breast cancer: prognosis, life expectancy, and more. > Breast Cancer >Home
  29. Sobani ZA, Saeed Z, Baloch HA, et al (2012). Knowledge attitude and practices among urban women of Karachi, Pakistan, regarding breast cancer. JPMA, 62, 1259.
  30. Tewari M, Pradhan S, Singh U, et al (2007). Estrogen and progesterone receptor status in breast Cancer: effect of oral contraceptive pills and hormone replacement therapy. Breast, 16, 540-5.
  31. Welsh AW, Lannin DR, Young GS, et al (2012). Cytoplasmic estrogen receptor in breast cancer. Clin Cancer Res, 18, 118-26.
  32. Wolff AC, Hammond ME, Schwartz JN, et al (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45.
  33.,23 Oct 2015.